Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.

Transplantation - 27 Jun 2014

Robertsen Ida, Asberg Anders, Granseth Tone, Vethe Nils Tore, Akhlaghi Fatemeh, Ghareeb Mwlod, Molden Espen, Reier-Nilsen Morten, Holdaas Hallvard, Midtvedt Karsten

Abstract excerpt

BACKGROUND: Dyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transplant recipients (RTRs). Pharmacotherapy with mTOR inhibitors aggravates dyslipidemia, thus necessitating lipid-lowering therapy with fluvastatin, pravastatin, or atorvastatin. These agent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Interactions
Share to Drug Substitution
Share to Dyslipidemias

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Fatty Acids, Monounsaturated

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Rosuvastatin Calcium

Share to Sirolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 24521776
DOI: 10.1097/01.TP.0000443225.66960.7e
PMCID: PMC4127422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24521776-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.PMID 24521776Read ↗

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function.Semantic proximity Read ↗

Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment.Semantic proximity Read ↗

Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin.Semantic proximity Read ↗

The influence of herbal medicine ursolic acid on the uptake of rosuvastatin mediated by OATP1B1*1a and *5.Semantic proximity Read ↗

No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.Semantic proximity Read ↗

The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.Semantic proximity Read ↗

Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease.Semantic proximity Read ↗

Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.